• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Johnson & Johnson Reports Q1 2025 Results

    4/15/25 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    • 2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%*
    • 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%*
    • Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA
    • Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition
    • Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, Company maintains Full-Year 2025 adjusted reported EPS4 outlook of 6.2%* growth at the mid-point

    Johnson & Johnson (NYSE:JNJ) today announced results for first-quarter 2025. "The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition."

    Overall financial results

     

    Q1

    ($ in Millions, expect EPS)

    2025

     

    2024

     

    % Change

    Reported Sales

    $21,893

     

    $ 21,383

     

    2.4%

    Net Earnings

    $10,999

     

    $3,255

     

    237.9%

    EPS (diluted)

    $4.54

     

    $1.34

     

    238.8%

     

     

     

    Q1

    Non-GAAP* ($ in Millions, except EPS)

    2025

     

    2024

     

    % Change

    Operational Sales1,2

     

     

     

     

    4.2%

    Adjusted Operational Sales1,3

     

     

     

     

    3.3%

    Adjusted Net Earnings1,4

    $6,706

     

    $6,580

     

    1.9%

    Adjusted EPS (diluted)1,4

    $2.77

     

    $2.71

     

    2.2%

    Free Cash Flow6,7

    ~$3,400

     

    $2,850

     

     

    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency

    4

    Excludes intangible amortization expense and special items

    5

    Excludes COVID-19 Vaccine

    6

    Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

    7

    First-quarter 2025 is estimated as of April 15, 2025

    Note: values may have been rounded

    Regional sales results

    Q1

     

     

     

    % Change

     

    ($ in Millions)

    2025

    2024

    Reported

    Operational1,2

    Currency

    Adjusted

    Operational1,3

    U.S.

    $12,305

    $11,620

    5.9%

    5.9

    -

    4.4

    International

    9,588

    9,763

    (1.8)

    2.1

    (3.9)

    1.9

    Worldwide

    $21,893

    $21,383

    2.4%

    4.2

    (1.8)

    3.3

    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

     

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency

    Note: values may have been rounded

    Segment sales results

    Q1

     

     

     

    % Change

     

    ($ in Millions)

    2025

    2024

    Reported

    Operational1,2

    Currency

    Adjusted

    Operational1,3

    Innovative Medicine

    $13,873

    $13,562

    2.3%

    4.2

    (1.9)

    4.4

    MedTech

    8,020

    7,821

    2.5

    4.1

    (1.6)

    1.3

    Worldwide

    $21,893

    $21,383

    2.4%

    4.2

    (1.8)

    3.3

    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

     

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency

    Note: values may have been rounded

    First-Quarter 2025 segment commentary:

    Operational sales* reflected below excludes the impact of translational currency.

    Innovative Medicine

    Innovative Medicine worldwide operational sales grew 4.2%* driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, SPRAVATO in Neuroscience, and XARELTO in Cardiovascular/Metabolism/Other. Growth was partially offset by an approximate (810) basis points impact from STELARA in Immunology.

    MedTech

    MedTech worldwide operational sales grew 4.1%*, with net acquisitions and divestitures positively impacting growth by 2.8%. Growth was driven primarily by Abiomed in Cardiovascular and wound closure products in General Surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics.

    Full-year 2025 guidance:

    Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

    ($ in Billions, except EPS)

    April 2025

    January 2025

    Adjusted Operational Sales1,2,5

    Change vs. Prior Year / Mid-point

    2.0% – 3.0% / 2.5%

    2.0% – 3.0% / 2.5%

    Operational Sales2,5 / Mid-point

    Change vs. Prior Year / Mid-point

    $91.6B – $92.4B / $92.0B

    3.3% – 4.3% / 3.8%

    $90.9B – $91.7B / $91.3B

    2.5% – 3.5% / 3.0%

    Estimated Reported Sales3,5/ Mid-point

    Change vs. Prior Year / Mid-point

    $91.0B – $91.8B / $91.4B

    2.6% – 3.6% / 3.1%

    $89.2B – $90.0B / $89.6B

    0.5% – 1.5% / 1.0%

    Adjusted Operational EPS (Diluted)2,4 / Mid-point

    Change vs. Prior Year / Mid-point

    $10.50 – $10.70 / $10.60

    5.2% – 7.2% / 6.2%

    $10.75 – $10.95 / $10.85

    7.7% – 9.7% / 8.7%

    Adjusted EPS (Diluted)3,4 / Mid-point

    Change vs. Prior Year / Mid-point

    $10.50 – $10.70 / $10.60

    5.2% – 7.2% / 6.2%

    $10.50 – $10.70 / $10.60

    5.2% – 7.2% / 6.2%

    1

    Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

    2

    Non-GAAP financial measure; excludes the impact of translational currency

    3

    Calculated using Euro Average Rate: April 2025 = $1.10 and January 2025 = $1.04 (Illustrative purposes only)

    4

    Non-GAAP financial measure; excludes intangible amortization expense and special items

    5

    Excludes COVID-19 Vaccine

    Note: percentages may have been rounded

    Other modeling considerations will be provided on the webcast.

    Notable announcements in the quarter:

    The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company's website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com.

    Regulatory

    European Commission approves subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer1

    Press Release

     

    European Commission approves Johnson & Johnson's subcutaneous DARZALEX (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility1

    Press Release

     

    U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease

    Press Release

     

    Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation

    Press Release

    Data Releases

    Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA Robotic Surgical System1

    Press Release

     

    Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill1

    Press Release

     

    Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)1

    Press Release

    TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis1

    Press Release

     

    Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25

    Press Release

     

    RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

    Press Release

    New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

    Press Release

    RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

    Press Release

    Johnson & Johnson MedTech Showcases New Era of Digital Orthopaedics at AAOS 2025

    Press Release

    Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

    Press Release

    Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

    Press Release

    TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

    Press Release

    New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

    Press Release

    Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

    Press Release

     

    Product Launch

    Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions

    Press Release

     

    Other

    Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership1

    Press Release

     

    Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims1

    Press Release

     

    Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

    Press Release

     

    Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

    Press Release

     
    1 Subsequent to the quarter

    Webcast information:

    Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

    About Johnson & Johnson:

    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

    Non-GAAP financial measures:

    * "Operational sales growth" excluding the impact of translational currency, "adjusted operational sales growth" excluding the net impact of acquisitions and divestitures and translational currency, as well as "adjusted net earnings", "adjusted diluted earnings per share" and "adjusted operational diluted earnings per share" excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

    Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

    Note to investors concerning forward-looking statements:

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

     
    Johnson & Johnson and Subsidiaries
    Supplementary Sales Data
     
    (Unaudited; Dollars in Millions) FIRST QUARTER

     

     

     

     

    Percent Change

    2025

     

    2024

     

    Total

     

    Operations

     

    Currency

    Sales to customers by
    segment of business
     
    Innovative Medicine
    U.S.

    $

    8,092

    7,612

    6.3

     

    %

    6.3

    -

     

    International

     

    5,781

    5,950

    (2.9

    )

    1.5

    (4.4

    )

     

    13,873

    13,562

    2.3

     

    4.2

    (1.9

    )

     
    MedTech
    U.S.

     

    4,213

    4,008

    5.1

     

    5.1

    -

     

    International

     

    3,807

    3,813

    (0.2

    )

    3.0

    (3.2

    )

     

    8,020

    7,821

    2.5

     

    4.1

    (1.6

    )

     
    U.S.

     

    12,305

    11,620

    5.9

     

    5.9

    -

     

    International

     

    9,588

    9,763

    (1.8

    )

    2.1

    (3.9

    )

    Worldwide

    $

    21,893

    21,383

    2.4

     

    %

    4.2

    (1.8

    )

     
    Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
    Johnson & Johnson and Subsidiaries
    Supplementary Sales Data
     
    (Unaudited; Dollars in Millions) FIRST QUARTER

     

     

     

     

    Percent Change

    2025

     

    2024

     

    Total

    Operations

     

    Currency

    Sales to customers by
    geographic area
     
    U.S.

    $

    12,305

    11,620

    5.9

     

    %

    5.9

     

    -

     

     
    Europe

     

    5,110

    5,163

    (1.0

    )

    2.2

     

    (3.2

    )

    Western Hemisphere excluding U.S.

     

    1,167

    1,194

    (2.3

    )

    9.2

     

    (11.5

    )

    Asia-Pacific, Africa

     

    3,311

    3,406

    (2.8

    )

    (0.6

    )

    (2.2

    )

    International

     

    9,588

    9,763

    (1.8

    )

    2.1

     

    (3.9

    )

     
    Worldwide

    $

    21,893

    21,383

    2.4

     

    %

    4.2

     

    (1.8

    )

     
    Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
    Johnson & Johnson and Subsidiaries
    Condensed Consolidated Statement of Earnings
     
    (Unaudited; in Millions Except Per Share Figures) FIRST QUARTER
     

    2025

     

    2024

     

    Percent

     

     

    Percent

     

     

     

    Percent

     

    Increase

    Amount

     

    to Sales

     

    Amount

     

    to Sales

     

    (Decrease)

    Sales to customers

    $

    21,893

     

    100.0

     

    $

    21,383

     

    100.0

     

    2.4

     

    Cost of products sold

     

    7,357

     

    33.6

     

     

    6,511

     

    30.4

     

    13.0

     

    Gross Profit

     

    14,536

     

    66.4

     

     

    14,872

     

    69.6

     

    (2.3

    )

    Selling, marketing and administrative expenses

     

    5,112

     

    23.3

     

     

    5,257

     

    24.6

     

    (2.8

    )

    Research and development expense

     

    3,225

     

    14.7

     

     

    3,542

     

    16.6

     

    (8.9

    )

    Interest (income) expense, net

     

    (128

    )

    (0.6

    )

     

    (209

    )

    (1.0

    )

    Other (income) expense, net

     

    (7,321

    )

    (33.4

    )

     

    2,404

     

    11.2

     

    Restructuring

     

    17

     

    0.1

     

     

    164

     

    0.8

     

    Earnings before provision for taxes on income

     

    13,631

     

    62.3

     

     

    3,714

     

    17.4

     

    267.0

     

    Provision for taxes on income

     

    2,632

     

    12.1

     

     

    459

     

    2.2

     

    473.4

     

    Net earnings

    $

    10,999

     

    50.2

     

    $

    3,255

     

    15.2

     

    237.9

     

     
    Net earnings per share (Diluted)

    $

    4.54

     

    $

    1.34

     

    238.8

     

     
    Average shares outstanding (Diluted)

     

    2,423.8

     

     

    2,430.1

     

     
    Effective tax rate

     

    19.3

     

    %

     

    12.4

     

    %

     
    Adjusted earnings before provision for taxes and net earnings (1)
    Earnings before provision for taxes on income

    $

    8,011

     

    36.6

     

    $

    7,877

     

    36.8

     

    1.7

     

    Net earnings

    $

    6,706

     

    30.6

     

    $

    6,580

     

    30.8

     

    1.9

     

    Net earnings per share (Diluted)

    $

    2.77

     

    $

    2.71

     

    2.2

     

    Effective tax rate

     

    16.3

     

    %

     

    16.5

     

    %

     
    (1) See Reconciliation of Non-GAAP Financial Measures.
    Johnson & Johnson and Subsidiaries
    Reconciliation of Non-GAAP Financial Measures
     
    First Quarter
    (Dollars in Millions Except Per Share Data)

    2025

    2024

    Net Earnings, after tax- as reported

    $10,999

    $3,255

     
    Pre-tax Adjustments
    Litigation related

    (6,966)

    2,726

    Intangible Asset Amortization expense

    1,120

    1,078

    Restructuring related 1

    55

    171

    Acquisition, integration and divestiture related

    132

    148

    (Gains)/losses on securities

    39

    (20)

    Medical Device Regulation

    -

    51

    COVID-19 Vaccine related costs

    -

    9

     
    Tax Adjustments
    Tax impact on special item adjustments 2

    1,315

    (856)

    Tax legislation and other tax related

    12

    18

    Adjusted Net Earnings, after tax

    $6,706

    $6,580

    Average shares outstanding (Diluted)

    2,423.8

    2,430.1

    Adjusted net earnings per share (Diluted)

    $2.77

    $2.71

    Operational adjusted net earnings per share (Diluted)

    $2.81

     
    Notes:

    1

    In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $144 million in the fiscal first quarter of 2024 include the termination of partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024.
     
    In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $55 million in the fiscal first quarter of 2025 and $27 million in the fiscal first quarter of 2024 primarily includes costs related to market and product exits.
     

    2

    The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
     
    Johnson & Johnson and Subsidiaries
    Reconciliation of Non-GAAP Financial Measure
     
    Adjusted Operational Sales Growth
    FIRST QUARTER 2025 ACTUAL vs. 2024 ACTUAL
       
    Segments
     
    Innovative Medicine MedTech Total
     
    WW As Reported

    2.3%

     

    2.5%

     

    2.4%

    U.S.

    6.3%

     

    5.1%

     

    5.9%

    International

    (2.9)%

     

    (0.2)%

     

    (1.8)%

     

     

     

     

     

    WW Currency

    (1.9)

     

    (1.6)

     

    (1.8)

    U.S.

    -

     

    -

     

    -

    International

    (4.4)

     

    (3.2)

     

    (3.9)

     

     

     

     

     

    WW Operational

    4.2%

     

    4.1%

     

    4.2%

    U.S.

    6.3%

     

    5.1%

     

    5.9%

    International

    1.5%

     

    3.0%

     

    2.1%

     

     

     

     

     

    Shockwave

     

     

    (3.3)

     

    (1.2)

    U.S.

     

     

    (5.1)

     

    (1.8)

    International

     

     

    (1.4)

     

    (0.5)

     

     

     

     

     

    All Other Acquisitions and Divestitures (A&D)

    0.2

     

    0.5

     

    0.3

    U.S.

    0.0

     

    0.9

     

    0.3

    International

    0.4

     

    0.2

     

    0.3

     

     

     

     

     

    WW Adjusted Operational Ex A&D

    4.4%

     

    1.3%

     

    3.3%

    U.S.

    6.3%

     

    0.9%

     

    4.4%

    International

    1.9%

     

    1.8%

     

    1.9%

     
     
    Note: Percentages are based on actual, non-rounded figures and may not sum

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FIRST QUARTER
    % Change
    INNOVATIVE MEDICINE SEGMENT (2)

    2025

    2024

    Reported

    Operational (1)

    Currency

     
    ONCOLOGY
    US

    $ 3,013

    2,383

    26.4

    %

    26.4

    %

    -

     

    Intl

    2,664

    2,430

    9.6

    %

    14.4

    %

    -4.8

    %

    WW

    5,678

    4,814

    17.9

    %

    20.4

    %

    -2.5

    %

    CARVYKTI
    US

    318

    140

    *

    *

    -

     

    Intl

    51

    16

    *

    *

    *

    WW

    369

    157

    *

    *

    *

    DARZALEX
    US

    1,829

    1,464

    24.9

    %

    24.9

    %

    -

     

    Intl

    1,409

    1,228

    14.7

    %

    19.8

    %

    -5.1

    %

    WW

    3,237

    2,692

    20.3

    %

    22.5

    %

    -2.2

    %

    ERLEADA
    US

    292

    285

    2.5

    %

    2.5

    %

    -

     

    Intl

    479

    404

    18.5

    %

    23.1

    %

    -4.6

    %

    WW

    771

    689

    11.9

    %

    14.6

    %

    -2.7

    %

    IMBRUVICA
    US

    235

    265

    -11.5

    %

    -11.5

    %

    -

     

    Intl

    474

    518

    -8.5

    %

    -4.2

    %

    -4.3

    %

    WW

    709

    784

    -9.5

    %

    -6.7

    %

    -2.8

    %

    RYBREVANT / LAZCLUZE (3)
    US

    113

    36

    *

    *

    -

     

    Intl

    28

    11

    *

    *

    *

    WW

    141

    47

    *

    *

    *

    TALVEY (3)
    US

    68

    50

    35.2

    %

    35.2

    %

    -

     

    Intl

    18

    8

    *

    *

    *

    WW

    86

    58

    48.4

    %

    50.2

    %

    -1.8

    %

    TECVAYLI
    US

    105

    101

    4.9

    %

    4.9

    %

    -

     

    Intl

    46

    33

    38.8

    %

    45.9

    %

    -7.1

    %

    WW

    151

    133

    13.3

    %

    15.0

    %

    -1.7

    %

    ZYTIGA / abiraterone acetate
    US

    7

    9

    -24.3

    %

    -24.3

    %

    -

     

    Intl

    118

    172

    -31.3

    %

    -28.5

    %

    -2.8

    %

    WW

    125

    181

    -30.9

    %

    -28.3

    %

    -2.6

    %

    OTHER ONCOLOGY (3)
    US

    47

    33

    42.9

    %

    42.9

    %

    -

     

    Intl

    42

    41

    4.6

    %

    10.1

    %

    -5.5

    %

    WW

    89

    73

    21.7

    %

    24.7

    %

    -3.0

    %

     
     
    See footnotes at end of schedule
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FIRST QUARTER
    % Change

    2025

    2024

    Reported

    Operational (1)

    Currency

    IMMUNOLOGY
    US

    2,196

    2,453

    -10.5

    %

    -10.5

    %

    -

     

    Intl

    1,510

    1,794

    -15.8

    %

    -11.5

    %

    -4.3

    %

    WW

    3,707

    4,247

    -12.7

    %

    -10.9

    %

    -1.8

    %

    REMICADE
    US

    314

    266

    18.1

    %

    18.1

    %

    -

     

    US Exports (4)

    10

    27

    -64.2

    %

    -64.2

    %

    -

     

    Intl

    143

    141

    1.3

    %

    6.8

    %

    -5.5

    %

    WW

    467

    434

    7.5

    %

    9.3

    %

    -1.8

    %

    SIMPONI / SIMPONI ARIA
    US

    292

    254

    14.8

    %

    14.8

    %

    -

     

    Intl

    366

    299

    22.4

    %

    29.7

    %

    -7.3

    %

    WW

    659

    554

    18.9

    %

    22.9

    %

    -4.0

    %

    STELARA
    US

    981

    1,396

    -29.8

    %

    -29.8

    %

    -

     

    Intl

    644

    1,055

    -38.9

    %

    -35.8

    %

    -3.1

    %

    WW

    1,625

    2,451

    -33.7

    %

    -32.3

    %

    -1.4

    %

    TREMFYA
    US

    599

    509

    17.6

    %

    17.6

    %

    -

     

    Intl

    356

    299

    19.2

    %

    24.4

    %

    -5.2

    %

    WW

    956

    808

    18.2

    %

    20.1

    %

    -1.9

    %

    OTHER IMMUNOLOGY
    US

    1

    0

    *

    *

    -

     

    Intl

    0

    0

    -

     

    -

     

    -

     

    WW

    1

    0

    *

    *

    -

     

    NEUROSCIENCE
    US

    968

    1,054

    -8.1

    %

    -8.1

    %

    -

     

    Intl

    679

    749

    -9.3

    %

    -5.5

    %

    -3.8

    %

    WW

    1,647

    1,803

    -8.6

    %

    -7.0

    %

    -1.6

    %

    CONCERTA / Methylphenidate
    US

    38

    41

    -7.4

    %

    -7.4

    %

    -

     

    Intl

    110

    136

    -18.9

    %

    -15.2

    %

    -3.7

    %

    WW

    148

    177

    -16.3

    %

    -13.4

    %

    -2.9

    %

    INVEGA SUSTENNA / XEPLION /

    INVEGA TRINZA / TREVICTA
    US

    625

    765

    -18.2

    %

    -18.2

    %

    -

     

    Intl

    277

    292

    -4.9

    %

    -1.1

    %

    -3.8

    %

    WW

    903

    1,056

    -14.5

    %

    -13.5

    %

    -1.0

    %

    SPRAVATO
    US

    276

    191

    45.0

    %

    45.0

    %

    -

     

    Intl

    43

    34

    25.0

    %

    31.7

    %

    -6.7

    %

    WW

    320

    225

    41.9

    %

    42.9

    %

    -1.0

    %

    OTHER NEUROSCIENCE
    US

    28

    58

    -50.6

    %

    -50.6

    %

    -

     

    Intl

    248

    287

    -13.4

    %

    -9.8

    %

    -3.6

    %

    WW

    277

    345

    -19.6

    %

    -16.7

    %

    -2.9

    %

     
     
    See footnotes at end of schedule
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FIRST QUARTER
    % Change

    2025

    2024

    Reported

    Operational (1)

    Currency

    PULMONARY HYPERTENSION
    US

    744

    766

    -2.9

    %

    -2.9

    %

    -

     

    Intl

    281

    283

    -0.6

    %

    3.2

    %

    -3.8

    %

    WW

    1,025

    1,049

    -2.3

    %

    -1.2

    %

    -1.1

    %

    OPSUMIT / OPSYNVI (3)
    US

    363

    356

    2.1

    %

    2.1

    %

    -

     

    Intl

    159

    169

    -6.0

    %

    -2.5

    %

    -3.5

    %

    WW

    522

    524

    -0.5

    %

    0.6

    %

    -1.1

    %

    UPTRAVI
    US

    365

    392

    -6.9

    %

    -6.9

    %

    -

     

    Intl

    86

    76

    13.4

    %

    17.5

    %

    -4.1

    %

    WW

    451

    468

    -3.6

    %

    -2.9

    %

    -0.7

    %

    OTHER PULMONARY HYPERTENSION(3)
    US

    15

    18

    -12.7

    %

    -12.7

    %

    -

     

    Intl

    37

    39

    -4.6

    %

    -0.3

    %

    -4.3

    %

    WW

    52

    56

    -7.2

    %

    -4.3

    %

    -2.9

    %

    INFECTIOUS DISEASES
    US

    315

    324

    -2.8

    %

    -2.8

    %

    -

     

    Intl

    487

    497

    -1.9

    %

    1.9

    %

    -3.8

    %

    WW

    802

    821

    -2.2

    %

    0.1

    %

    -2.3

    %

    EDURANT / rilpivirine
    US

    8

    8

    -1.3

    %

    -1.3

    %

    -

     

    Intl

    350

    315

    11.0

    %

    14.7

    %

    -3.7

    %

    WW

    358

    323

    10.7

    %

    14.3

    %

    -3.6

    %

    PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
    US

    305

    314

    -2.9

    %

    -2.9

    %

    -

     

    Intl

    98

    104

    -6.2

    %

    -0.6

    %

    -5.6

    %

    WW

    403

    418

    -3.7

    %

    -2.3

    %

    -1.4

    %

    OTHER INFECTIOUS DISEASES (3)
    US

    2

    2

    7.7

    %

    7.7

    %

    -

     

    Intl

    39

    77

    -48.8

    %

    -47.0

    %

    -1.8

    %

    WW

    41

    78

    -47.6

    %

    -45.9

    %

    -1.7

    %

    CARDIOVASCULAR / METABOLISM / OTHER
    US

    855

    631

    35.4

    %

    35.4

    %

    -

     

    Intl

    158

    197

    -19.7

    %

    -15.3

    %

    -4.4

    %

    WW

    1,013

    829

    22.3

    %

    23.4

    %

    -1.1

    %

    XARELTO
    US

    690

    518

    33.3

    %

    33.3

    %

    -

     

    Intl

    -

    -

    -

     

    -

     

    -

     

    WW

    690

    518

    33.3

    %

    33.3

    %

    -

     

    OTHER
    US

    165

    114

    45.0

    %

    45.0

    %

    -

     

    Intl

    158

    197

    -19.7

    %

    -15.3

    %

    -4.4

    %

    WW

    323

    311

    3.9

    %

    6.7

    %

    -2.8

    %

     
    TOTAL INNOVATIVE MEDICINE
    US

    8,092

    7,612

    6.3

    %

    6.3

    %

    -

     

    Intl

    5,781

    5,950

    -2.9

    %

    1.5

    %

    -4.4

    %

    WW

    $ 13,873

    13,562

    2.3

    %

    4.2

    %

    -1.9

    %

     
     
    See footnotes at end of schedule
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FIRST QUARTER

     

     

     

    % Change

    MEDTECH SEGMENT (2)

     

    2025

    2024

    Reported

    Operational (1)

    Currency

     
    CARDIOVASCULAR
    US

    $ 1,261

    1,025

    23.0

    %

    23.0

    %

    -

     

    Intl

    842

    781

    7.8

    %

    10.7

    %

    -2.9

    %

    WW

    2,103

    1,806

    16.4

    %

    17.7

    %

    -1.3

    %

    ELECTROPHYSIOLOGY
    US

    684

    692

    -1.1

    %

    -1.1

    %

    -

     

    Intl

    638

    652

    -2.0

    %

    0.7

    %

    -2.7

    %

    WW

    1,323

    1,344

    -1.6

    %

    -0.2

    %

    -1.4

    %

    ABIOMED
    US

    339

    303

    11.9

    %

    11.9

    %

    -

     

    Intl

    81

    67

    19.7

    %

    23.6

    %

    -3.9

    %

    WW

    420

    371

    13.3

    %

    14.0

    %

    -0.7

    %

    SHOCKWAVE (5)
    US

    206

    -

    *

     

    *

    -

     

    Intl

    52

    -

    *

     

    *

    -

     

    WW

    258

    -

    *

     

    *

    -

     

    OTHER CARDIOVASCULAR
    US

    32

    30

    7.1

    %

    7.1

    %

    -

     

    Intl

    72

    62

    15.1

    %

    17.4

    %

    -2.3

    %

    WW

    103

    92

    12.5

    %

    14.1

    %

    -1.6

    %

    ORTHOPAEDICS
    US

    1,384

    1,448

    -4.4

    %

    -4.4

    %

    -

     

    Intl

    857

    892

    -3.9

    %

    -0.9

    %

    -3.0

    %

    WW

    2,241

    2,340

    -4.2

    %

    -3.1

    %

    -1.1

    %

    HIPS
    US

    263

    270

    -2.5

    %

    -2.5

    %

    -

     

    Intl

    146

    152

    -4.0

    %

    -0.8

    %

    -3.2

    %

    WW

    409

    422

    -3.1

    %

    -1.9

    %

    -1.2

    %

    KNEES
    US

    231

    242

    -4.3

    %

    -4.3

    %

    -

     

    Intl

    158

    160

    -1.0

    %

    2.1

    %

    -3.1

    %

    WW

    389

    401

    -3.0

    %

    -1.7

    %

    -1.3

    %

    TRAUMA
    US

    502

    504

    -0.5

    %

    -0.5

    %

    -

     

    Intl

    270

    261

    3.7

    %

    7.2

    %

    -3.5

    %

    WW

    772

    765

    0.9

    %

    2.1

    %

    -1.2

    %

    SPINE, SPORTS & OTHER
    US

    388

    432

    -10.2

    %

    -10.2

    %

    -

     

    Intl

    283

    320

    -11.6

    %

    -8.9

    %

    -2.7

    %

    WW

    671

    752

    -10.8

    %

    -9.7

    %

    -1.1

    %

     
     
    See footnotes at end of schedule
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FIRST QUARTER

     

     

     

    % Change

     

    2025

    2024

    Reported

    Operational (1)

    Currency

    SURGERY
    US

    1,002

    987

    1.5

    %

    1.5

    %

    -

     

    Intl

    1,394

    1,429

    -2.5

    %

    0.8

    %

    -3.3

    %

    WW

    2,396

    2,416

    -0.8

    %

    1.1

    %

    -1.9

    %

    ADVANCED
    US

    457

    446

    2.7

    %

    2.7

    %

    -

     

    Intl

    616

    641

    -4.0

    %

    -1.0

    %

    -3.0

    %

    WW

    1,073

    1,087

    -1.2

    %

    0.5

    %

    -1.7

    %

    GENERAL
    US

    544

    542

    0.5

    %

    0.5

    %

    -

     

    Intl

    778

    788

    -1.2

    %

    2.3

    %

    -3.5

    %

    WW

    1,323

    1,330

    -0.5

    %

    1.6

    %

    -2.1

    %

    VISION
    US

    566

    547

    3.4

    %

    3.4

    %

    -

     

    Intl

    713

    710

    0.4

    %

    3.9

    %

    -3.5

    %

    WW

    1,279

    1,258

    1.7

    %

    3.7

    %

    -2.0

    %

    CONTACT LENSES / OTHER
    US

    452

    438

    3.1

    %

    3.1

    %

    -

     

    Intl

    467

    472

    -1.1

    %

    2.4

    %

    -3.5

    %

    WW

    919

    910

    1.0

    %

    2.7

    %

    -1.7

    %

    SURGICAL
    US

    114

    110

    4.3

    %

    4.3

    %

    -

     

    Intl

    246

    238

    3.4

    %

    7.1

    %

    -3.7

    %

    WW

    361

    348

    3.7

    %

    6.2

    %

    -2.5

    %

     
    TOTAL MEDTECH
    US

    4,213

    4,008

    5.1

    %

    5.1

    %

    -

     

    Intl

    3,807

    3,813

    -0.2

    %

    3.0

    %

    -3.2

    %

    WW

    $ 8,020

    7,821

    2.5

    %

    4.1

    %

    -1.6

    %

     
    Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
    * Percentage greater than 100% or not meaningful
    (1) Operational growth excludes the effect of translational currency
    (2) Unaudited
    (3) See Supplemental Sales Information Schedule
    (4) Reported as U.S. sales
    (5) Acquired on May 31, 2024
    Supplemental Sales Information (Unaudited)
    (Dollars in Millions)
     
     

    2023

     

    2024

     

    2024

     

     

     

     

     

     

     

     

     

     

     

    Full Year

    Q1

    Q2

    Q3

    Q4

     

    Full Year

    INNOVATIVE MEDICINE SEGMENT
     
    ONCOLOGY
    RYBREVANT / LAZCLUZE
    US

    66

    36

    52

    68

    101

    257

    INTL

    27

    11

    17

    21

    21

    70

    WW

    93

    47

    69

    89

    122

    327

     
    TALVEY
    US

    56

    50

    59

    64

    68

    241

    INTL

    7

    8

    9

    12

    17

    46

    WW

    63

    58

    69

    75

    85

    287

     
    OTHER ONCOLOGY
    US

    93

    33

    37

    36

    39

    145

    INTL

    235

    41

    45

    50

    36

    172

    WW

    328

    73

    83

    86

    75

    317

     
    PULMONARY HYPERTENSION
    OPSUMIT / OPSYNVI
    US

    1,292

    356

    376

    417

    408

    1,557

    INTL

    681

    169

    171

    166

    162

    668

    WW

    1,973

    524

    548

    583

    570

    2,225

     
    OTHER PULMONARY HYPERTENSION
    US

    79

    18

    17

    21

    19

    75

    INTL

    182

    39

    49

    39

    38

    165

    WW

    260

    56

    67

    60

    57

    240

     
    INFECTIOUS DISEASES
    OTHER INFECTIOUS DISEASES (1)
    US

    19

    2

    5

    3

    1

    11

    INTL

    1,395

    77

    227

    54

    43

    401

    WW

    1,414

    78

    233

    56

    45

    412

    Note: Columns and rows within tables may not add due to rounding
    (1) Other Infectious Diseases is inclusive of COVID-19 Vaccine sales, which were previously disclosed separately
    Johnson & Johnson and Subsidiaries
    GAAP to Non-GAAP Reconciliation
    $ in Millions
    Year to Date
    Innovative Medicine

    First Quarter

    March 30,

    2025

    GAAP

     

    Intangible asset

    amortization

     

    Litigation

    related

     

    Restructuring

    related

     

    Acquisition,

    integration and

    divestiture related

     

    (Loss)/gain on

    securities

     

    Tax legislation

    and other tax

    related

     

    First Quarter

    March 30,

    2025

    Non-GAAP

    Cost of products sold

    $

    4,020

     

    (649

    )

    3,371

     

    Selling, marketing and admin expenses

     

    2,261

     

    2,261

     

    Research and development expense

     

    2,548

     

    2,548

     

    Other segment items

     

    (166

    )

    -

     

    -

     

    -

     

    (20

    )

    (18

    )

    -

     

    (204

    )

    Adjusted Income Before Tax by Segment

     

    5,210

     

    649

     

    -

     

    -

     

    20

     

    18

     

    -

     

    5,897

     

     
    MedTech

    First Quarter

    March 30,

    2025

    GAAP

     

    Intangible asset

    amortization

     

    Litigation

    related

     

    Restructuring

    related

     

    Acquisition,

    integration and

    divestiture related

     

    (Loss)/gain on

    securities

     

    Tax legislation

    and other tax

    related

     

    First Quarter

    March 30,

    2025

    Non-GAAP

    Cost of products sold

    $

    3,326

     

    (471

    )

    (8

    )

    (52

    )

    2,795

     

    Selling, marketing and admin expenses

     

    2,656

     

    2,656

     

    Research and development expense

     

    677

     

    (6

    )

    671

     

    Other segment items

     

    (60

    )

    -

     

    -

     

    (47

    )

    (54

    )

    (21

    )

    -

     

    (182

    )

    Adjusted Income Before Tax by Segment

     

    1,421

     

    471

     

    -

     

    55

     

    112

     

    21

     

    -

     

    2,080

     

     
    Expenses not allocated to segments

    First Quarter

    March 30,

    2025

    GAAP

     

    Intangible asset

    amortization

     

    Litigation

    related

     

    Restructuring

    related

     

    Acquisition,

    integration and

    divestiture related

     

    (Loss)/gain on

    securities

     

    Tax legislation

    and other tax

    related

     

    First Quarter

    March 30,

    2025

    Non-GAAP

    Cost of products sold

    $

    11

     

    11

     

    Selling, marketing and admin expenses

     

    195

     

    195

     

    Research and development expense

    -

     

    Other segment items

     

    (7,206

    )

    -

     

    6,966

     

    -

     

    -

     

    -

     

    -

     

    (240

    )

    Adjusted Income Before Tax by Segment

     

    7,000

     

    -

     

    (6,966

    )

    -

     

    -

     

    -

     

    -

     

    34

     

     
    Johnson & Johnson Consolidated

    First Quarter

    March 30,

    2025

    GAAP

     

    Intangible asset

    amortization

     

    Litigation

    related

     

    Restructuring

    related

     

    Acquisition,

    integration and

    divestiture related

     

    (Loss)/gain on

    securities

     

    Tax legislation

    and other tax

    related

     

    First Quarter

    March 30,

    2025

    Non-GAAP

    Cost of products sold

    $

    7,357

     

    (1,120

    )

    (8

    )

    (52

    )

    -

     

    6,177

     

    Selling, marketing and admin expenses

     

    5,112

     

    5,112

     

    Research and development expense

     

    3,225

     

    (6

    )

    3,219

     

    Other (Income) / Expense

     

    (7,321

    )

    -

     

    6,966

     

    (30

    )

    (74

    )

    (39

    )

    (498

    )

    In-process research and development impairments

     

    -

     

    -

     

    Interest (Income)/Expense

     

    (128

    )

    (128

    )

    Restructuring

     

    17

     

    (17

    )

    -

     

    Adjusted Income Before Tax

     

    13,631

     

    1,120

     

    (6,966

    )

    55

     

    132

     

    39

     

    -

     

    8,011

     

    Provision for taxes on income

     

    2,632

     

    188

     

    (1,553

    )

    11

     

    30

     

    9

     

    (12

    )

    1,305

     

    Net Earnings

     

    10,999

     

    932

     

    (5,413

    )

    44

     

    102

     

    30

     

    12

     

    6,706

     

    Johnson & Johnson and Subsidiaries
    GAAP to Non-GAAP Reconciliation
    $ in Millions
    Year to Date
    Innovative Medicine First Quarter

    March 31, 2024

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Acquisition,

    integration and

    divestiture related
    (Loss)/gain on

    securities
    Medical Device

    Regulation
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    First Quarter

    March 31, 2024

    Non-GAAP
    Cost of products sold

    $

    3,370

     

    (698

    )

    (2

    )

    2,670

     

    Selling, marketing and admin expenses

     

    2,438

     

    2,438

     

    Research and development expense

     

    2,896

     

    (7

    )

    2,889

     

    Other segment items

     

    (111

    )

    (144

    )

    (47

    )

    55

     

    (247

    )

    Adjusted Income Before Tax by Segment

     

    4,969

     

    698

     

    -

     

    144

     

    47

     

    (55

    )

    -

     

    9

     

    -

     

    5,812

     

     
    MedTech First Quarter

    March 31, 2024

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Acquisition,

    integration and

    divestiture related
    (Loss)/gain on

    securities
    Medical Device

    Regulation
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    First Quarter

    March 31, 2024

    Non-GAAP
    Cost of products sold

    $

    3,120

     

    (380

    )

    (7

    )

    (20

    )

    2,713

     

    Selling, marketing and admin expenses

     

    2,582

     

    (4

    )

    2,578

     

    Research and development expense

     

    646

     

    (18

    )

    (27

    )

    601

     

    Other segment items

     

    (47

    )

    (20

    )

    (43

    )

    (22

    )

    (132

    )

    Adjusted Income Before Tax by Segment

     

    1,520

     

    380

     

    -

     

    27

     

    61

     

    22

     

    51

     

    -

     

    -

     

    2,061

     

     
    Expenses not allocated to segments First Quarter

    March 31, 2024

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Acquisition,

    integration and

    divestiture related
    (Loss)/gain on

    securities
    Medical Device

    Regulation
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    First Quarter

    March 31, 2024

    Non-GAAP
    Cost of products sold

    $

    21

     

    21

     

    Selling, marketing and admin expenses

     

    237

     

    237

     

    Research and development expense

     

    -

     

    -

     

    Other segment items

     

    2,517

     

    (2,726

    )

    (40

    )

    (13

    )

    (262

    )

    Adjusted Income Before Tax by Segment

     

    (2,775

    )

    -

     

    2,726

     

    -

     

    40

     

    13

     

    -

     

    -

     

    -

     

    4

     

     
    Johnson & Johnson Consolidated First Quarter

    March 31, 2024

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Acquisition,

    integration and

    divestiture related
    (Loss)/gain on

    securities
    Medical Device

    Regulation
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    First Quarter

    March 31, 2024

    Non-GAAP
    Cost of products sold

    $

    6,511

     

    (1,078

    )

    (7

    )

    (20

    )

    (2

    )

    5,404

     

    Selling, marketing and admin expenses

     

    5,257

     

    (4

    )

    5,253

     

    Research and development expense

     

    3,542

     

    (18

    )

    (27

    )

    (7

    )

    3,490

     

    Other (Income) / Expense

     

    2,404

     

    (2,726

    )

    (130

    )

    20

     

    (432

    )

    In-process research and development impairments

     

    -

     

    -

     

    Interest (Income)/Expense

     

    (209

    )

    (209

    )

    Restructuring

     

    164

     

    (164

    )

    -

     

    Adjusted Income Before Tax

     

    3,714

     

    1,078

     

    2,726

     

    171

     

    148

     

    (20

    )

    51

     

    9

     

    -

     

    7,877

     

    Provision for taxes on income

     

    459

     

    148

     

    627

     

    39

     

    38

     

    (7

    )

    9

     

    2

     

    (18

    )

    1,297

     

    Net Earnings

     

    3,255

     

    930

     

    2,099

     

    132

     

    110

     

    (13

    )

    42

     

    7

     

    18

     

    6,580

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250414807799/en/

    Media contact:

    [email protected]

    Investor contact:

    [email protected]

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    More analyst ratings

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    SEC Filings

    See more
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      5/7/25 4:47:35 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      4/30/25 4:30:48 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Johnson & Johnson

      10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

      4/23/25 4:04:45 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference

      Johnson & Johnson (NYSE:JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20250521120747/en/ Media contact: [email protected] Investor contact: [email protected]

      5/21/25 4:40:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

      ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma RARITAN, N.J., May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). An application for the approval of DARZALEX FASPRO® for adult patients with H

      5/20/25 6:21:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts

      Both decisions benefited plaintiffs harmed by using Johnson & Johnson's Baby Powder National plaintiffs firm Dean Omar Branham Shirley, LLP, has been recognized by ALM and Law.com for securing two of the largest jury verdicts of 2024. Both cases involved claims against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) over its talc-based Baby Powder, which exposed users to asbestos, a known carcinogen. The 29th-ranked case on the ALM list was a $260 million verdict in Oregon on behalf of Kyung Lee, a 49-year-old mother of three who was diagnosed with mesothelioma after lifelong use of J&J's Baby Powder. Jurors awarded $60 million in compensatory damages and $200 million in punitive damag

      5/20/25 12:24:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      2/13/24 5:07:58 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      1/30/24 12:46:49 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Financials

    Live finance-specific insights

    See more

    $JNJ
    Leadership Updates

    Live Leadership Updates

    See more
    • Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea

      4/15/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q1 2025 Results

      2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the

      4/15/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

      Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE:JNJ) (the "Company") subsidiary Red River Talc LLC ("Red River") to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants. Rather than pursue a protracted appeal, the Company will return to the tort system to litigate and defeat these merit

      3/31/25 10:20:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

      WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

      3/25/25 1:11:06 PM ET
      $JNJ
      $TVGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

      Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well

      3/4/25 4:15:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 92% to 29,795 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      5/5/25 5:10:14 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Woods Eugene A.

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:57:54 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director West Nadja

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      4/28/25 5:54:13 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care